Literature DB >> 20951785

Systemic exposure of quercetin after administration of feng-liao-chang-wei-kang granules to rats.

Junqing Zhang1, Xia Liu, Naiguang Fu, Mingsheng Liu, Yinfeng Tan.   

Abstract

AIM OF STUDY: The objective of this study was to observe the systemic exposure of quercetin (QCT) including its free and total concentration in rat blood samples following a single p.o. dose of feng-liao-chang-wei-kang granules (FLCWKG).
MATERIALS AND METHODS: Six male rats were given the FLCHKG and the serial blood samples were collected. Fully or partially validated LC/MS/MS methods were developed to analyze the resulting biosamples. Various pharmacokinetic (PK) parameters were estimated from the plasma concentration versus time data using non-compartmental methods.
RESULTS: Both methods for analysis of the free and total QCT plasma concentration are sensitive, specific, accurate and reliable. The PK parameters of free QCT after administration of FLCWKG, in comparison with total concentration, show a lower C(max) (32.4±8.2 ng/ml versus 164±49 ng/ml), a lower AUC(0→∞) (39.3±6.9 ng/ml h versus 313±16 ng/ml h), a shorter T(max) (0.17±0.00 h versus 0.83±1.01 h) and a similar t(1/2) (3.90±0.88 h versus 3.10±1.94 h), MRT(0→t) (2.27±0.10 h versus 2.86±0.41 h).
CONCLUSIONS: Free QCT was quickly absorbed from gastrointestinal tract and circulated in blood at quite low concentration. The circulating flavonoids originating from this formula were dominantly conjugated derivatives. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951785     DOI: 10.1016/j.jep.2010.10.014

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  1 in total

1.  Feng-Liao-Chang-Wei-Kang Combined with 5-Fluorouracil Synergistically Suppresses Colitis-Associated Colorectal Cancer via the IL-6/STAT3 Signalling Pathway.

Authors:  Lifan Zhong; Fan Yang; Lianfang Gan; Zhaoxin Yang; Shuhong Tian; Mianqing Huang; Chuanzhu Lv; Ling Huang
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.